The company said ersodetug reduced patients’ glucose infusion rate, a measure of how much sugar they need through an intravenous drip to prevent blood sugar from falling. Tumor hyperinsulinism is a rare condition in which abnormal tumors cause excessive insulin production or secretion, potentially leading to dangerously low blood sugar.

“We are thrilled with this outcome and what it means for individuals living with tumor hyperinsulinism,” Chief Executive Nevan Charles Elam said. He said Rezolute believes it is positioned to move both congenital HI and tumor HI into the approval process next year, and expects to discuss the programs with the FDA in the first quarter of 2027.

Separately, Rezolute announced the pricing of an underwritten offering of more than 22 million common shares at $3.87 each. It also plans to offer certain investors pre-funded warrants to buy up to 3.8 million common shares in place of shares. The offering is expected to close Monday and generate about $100 million in gross proceeds, before underwriting costs, commissions and other offering expenses.